Shares of Genfit S.A. (OTCMKTS:GNFTF – Get Free Report) fell 1% during mid-day trading on Monday . The company traded as low as $2.95 and last traded at $2.95. 150 shares were traded during mid-day trading, a decline of 88% from the average session volume of 1,225 shares. The stock had previously closed at $2.98.
Genfit Price Performance
The stock’s 50-day simple moving average is $3.18 and its 200-day simple moving average is $3.44.
About Genfit
Genfit SA, a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia.
Featured Articles
- Five stocks we like better than Genfit
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- The Charles Schwab Company Can Hit New Highs
- 3 Healthcare Dividend Stocks to Buy
- Costco vs. Walmart: Revenue Comparison of Two Retail Giants
- 3 Monster Growth Stocks to Buy Now
- 3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
Receive News & Ratings for Genfit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genfit and related companies with MarketBeat.com's FREE daily email newsletter.
